...
首页> 外文期刊>Molecular biotechnology >The substitution U_(475) → C with Sabin3-like mutation within the IRES attenuate Coxsackievirus B_3 cardiovirulence
【24h】

The substitution U_(475) → C with Sabin3-like mutation within the IRES attenuate Coxsackievirus B_3 cardiovirulence

机译:在IRES中用类似Sabin3的突变取代U_(475)→C减弱了柯萨奇病毒B_3的心脏毒性

获取原文
获取原文并翻译 | 示例
           

摘要

The Sabin3 mutation in the viral RNA plays an important role in directing attenuation phenotype of Sabin vaccine strain of poliovirus type 1 (PV1). We previously described that Sabin3-like mutation introduced in Coxsackievirus B3 (CVB3) genome led to a defective mutant. However, this mutation do not led to destruction of secondary structure motif C within the stem-loop V of CVB3 RNA because of the presence of one nucleotide difference (C → U) in the region encompassing the Sabin3 mutation at nucleotides 471 of PV1 and 475 of CVB3 RNA. In order to reproduce the same sequence of PV1 sabin3 vaccine strain, we introduce in this study an additional mutation (U475 → C) to CVB3 Sabin3-like mutant. Our results demonstrated that Sabin3-like+C mutant displayed a decreased translation initiation defects when translated in cell-free system. This translation initiation defect was correlated with reduced yields of infectious virus particles in HeLa cells in comparison with Sabin3-like mutant and wild-type CVB3 viruses. Inoculation of Swiss mice with mutant viruses resulted in no inflammatory heart disease when compared to heart of mice infected with wild-type. Theses findings indicate that the double mutant could be exploited for the development of a live attenuated vaccine against CVB3.
机译:病毒RNA中的Sabin3突变在指导脊髓灰质炎病毒1型(PV1)的Sabin疫苗株的减毒表型中起重要作用。我们以前描述过,柯萨奇病毒B3(CVB3)基因组中引入的Sabin3样突变导致缺陷突变。但是,此突变不会导致CVB3 RNA茎环V内二级结构基序C的破坏,因为在PV1和475核苷酸的471位分子中包含Sabin3突变的区域存在一个核苷酸差异(C→U)。 CVB3 RNA。为了复制PV1 sabin3疫苗株的相同序列,我们在本研究中引入了CVB3 Sabin3样突变体的另一个突变(U475→C)。我们的结果表明,当在无细胞系统中翻译时,Sabin3-like + C突变体显示出减少的翻译起始缺陷。与Sabin3样突变体和野生型CVB3病毒相比,此翻译起始缺陷与HeLa细胞中感染性病毒颗粒的产量降低相关。与感染野生型小鼠的心脏相比,用突变病毒接种瑞士小鼠不会导致炎症性心脏病。这些发现表明,双突变体可用于开发抗CVB3的减毒活疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号